All Posts

This week, Goodly Technologies travels to San Francisco as part of a delegation organised by the Bavarian State Ministry of Economic Affairs, Bayern innovativ. The trip brings together innovative Bavarian companies working at the exiting intersection of medical technology and artificial intelligence — for meetings with MedTech firms, AI giants and investors, and research institutions across the Bay Area.   Why San Francisco The Bay Area remains the global centre of gravity fo

With the official start of the BMFTR-funded project period, Goodly Technologies and the Department of Ophthalmology and Optometry at LMU University Hospital Munich (Klinikum der Universität München — Augenklinik und Poliklinik) formally begin joint development of the SeeCure diagnostic system.   A Partner at the Forefront of Ophthalmic Research The LMU Eye Clinic is among the most research-intensive ophthalmology departments in Europe, with deep expertise in retinal diseases,

The European Union's AI Act is not a future obligation — it is becoming binding now. Any organization that develops, deploys, or markets artificial intelligence systems affecting regulated industries — healthcare, pharmaceuticals, financial services — faces new compliance requirements that existing quality management frameworks were never designed to handle. Goodly Technologies is developing AI-QMS: a lean, modular compliance platform purpose-built for exactly this challenge.

Goodly Technologies receives federal funding from Germany's BMFTR for SeeCure — an AI-powered VR system that brings clinical eye diagnostics to care homes and private households.

Before Robert Hoffmeister co founded Goodly Technologies, he spent several years developing regulated software for pharmaceutical industry and ended up selling his enterprise tote where he worked as director XR software engineering before  he went on  to develop,  for teh last two years on one of the most technically and regulatory demanding projects : building a Virtual Reality-based primary efficacy endpoint for a gene therapy company's Phase I clinical trials — and plannin